The effects of DA-6034 on NF-κB activity induced by lipopolysaccharide or tumor necrosis factor α in a human colonic epithelial cell line

Hepato-Gastroenterology

Volumn 55, Issue 88, 2008, Pages 2059-2064

  Kim, Ji Won ^a   Kim, Bjeong Gwan ^a   Lee, Kook Lae ^a   Jeon, Ji Bong ^a   Jung, Yong Jin ^a   Kim, Joo Sung ^b   Jung, Hyun Chae ^b   Song, In Sung ^b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

DA 6034; Inflammatory bowel disease; Nuclear Factor B. lipopolysaccharid; Tumor necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; DA 6034; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CELL STRAIN HT29; COLON MUCOSA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL FRACTIONATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLAVONOIDS; HT29 CELLS; HUMANS; LIPOPOLYSACCHARIDES; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 60849095529     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sartor RB: Pathogenesis and immune mechanism of chronic inflammatory bowel disease. Am J Gastroenterol 1997; 02:5-11.
2. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337:1029-1035.
3. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA: Randomised controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease. Lancet 1997; 349:521-524.
4. Ina K, Kusugami K, Yamaguchi T, Imada A, Hosokawa T, Ohsuga M, Shinoda M, Ando T, Ito K, Yokoyama Y: Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am J Gastroenterol 1997; 92:1342-1346.
5. Barnes PJ, Karin M: Nuclear factor κB: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997; 336:1066-1071.
6. Tak PP, Firestein GS: NF-κB: a key role in inflammatory disease. J Clin Invest 2001; 107:7-11.
7. May MJ, Ghosh S: Signal transduction through NF-κB. Immunol Today 1998; 19:80-88.
8. Baldwin A Jr: The NF-kappa B and I kappa B preteins: new discoveries and insights. Annu Rev Immunol 1996; 14:649-683.
9. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, Gross V: Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 357-369.
10. Schottelius, AJ, Balbwin, AS: A role for transcription factor NF-κB in intestinal inflammation. Int J Colorectal Dis 1999; 14:18-28.
11. Schreiber S, Nikolaus S, Hampe J: Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 1998; 42: 477-485.
12. Neurath MF, Pettersson S, Meyer Z, Buschenfelde KH, Strober W: Local administration of antisense phosphrothioate oligonucleotides to the p65 subunit of NF-kappaB abrogates established experimental colitis in mice. Nat Med 1996; 2:998-1004.
13. Kim YS, Son M, Ko JI, Cho H, Yoo M, Kim WB, Song IS, Kim CY: Effect of DA-6034, a derivative of flavonoid, in experimental animal models of inflammatory bowel disease. Arch Pharmacol Res 1999; 22:354-360.
14. Singh S, Aggarwal BB: Activation of transcription factor NF-κB is suppressed by curcumin (diferulolylmethane). J Biol Chem 1995; 270:24995-25000.
15. Fitzpatrick LR, Wang J, Le T: Caffeic acid phenethyl ester, an inhibitor of nuclear factor κB, attenuate bacterial peptidoglycan polysaccharide-induced colitis in rats. J Pharmacol Exp Ther 2001; 299:915-920.
16. Schmid RM, Liptay S, Betts JC, Nabel GJ: Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction. J Biol Chem 1994; 269:32162-32167.
17. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B: Increased production of tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39:684-689.
18. Reinecker HC, Steffen M, Withoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A: Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94:174-181.
19. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM: Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571. Aliment Pharmacol Therapeut 1997; 11:1031-1035.
20. Cole AT, Pikington BJ, McLaughlan J, Smith C, Balsitis M, Hawkey CJ: Mucosal factors inducing neutrophil movement in ulcerative colitis: The role of interleukin-8 and interleukin B4. Gut 1996; 39:248-254.
21. Keshavarzian A, Fusunyan RD, Jacyno M, Winship D, MacDermott RP, Sanderson IR: Increased interleukin-8 in rectal dialysate from patients with ulcerative colitis: Evidence for a biological role for IL-8 in inflammation of the colon. Am J Gastroenterol 1999; 94:704-712.
22. Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101:1163-1174.
23. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, Lipsky JJ, Mckean DJ: Inhibition of interleukin-1-stimulated NF-kappaB RelA/ p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999; 274:26448-26453.
24. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, Matsushima K: Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene expression. J Biol Chem 1994; 269:13289-13295.
25. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity trhough induction of I kappa B synthesis. Science 1995; 270:286-290.